RAPP

Rapport Therapeutics Inc

Add to Watchlist

Advanced Chart

26.110

-0.25(-0.948%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

26.915

Open

26.250

VWAP

26.07

Vol

417.49K

Mkt Cap

1.20B

Low

25.550

Amount

10.89M

EV/EBITDA(TTM)

Total Shares

46.11M

943.57M

EV/OCF(TTM)

P/S(TTM)

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

8 Analyst Rating

Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 43.86 USD with a low forecast of 28.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 26.110

Low

28.00

Averages

43.86

High

56.00

Current: 26.110

Low

28.00

Averages

43.86

High

56.00

Truist

Joon Lee

Buy

initiated

$44

2025-09-16

Reason

Truist

Joon Lee

Price Target

$44

2025-09-16

initiated

Buy

Reason

Truist analyst Joon Lee initiated coverage of Rapport Therapeutics with a Buy rating and $44 price target. Rapport is focused on the central nervous system with a lead program in focal onset epilepsy, a therapeutic area worth $10B annually and growing, the analyst tells investors in a research note. The firm believes RAP-219's magnitude and speed of seizure reduction is \"impressive\" and models over$1B in peak sales in 2038 for focal onset epilepsy alone.

Goldman Sachs

Salveen Richter

maintain

$51

2025-09-12

Reason

Goldman Sachs

Salveen Richter

Price Target

$51

2025-09-12

maintain

Reason

Goldman Sachs analyst Salveen Richter assigned Rapport Therapeutics with a Buy rating and $51 price target from its Early-Stage Biotech designation. RAP-219's Phase 2 epilepsy data showed a 71% reduction in long episodes, the primary endpoint, with 24% achieving seizure freedom for the eight-week treatment period, the analyst tells investors in a research note. Goldman now views RAP-219 as well-positioned into the Phase 3 study given the Phase 2 \"de-risking.\"

H.C. Wainwright

Buy

upgrade

$31 -> $34

2025-09-08

Reason

H.C. Wainwright

Price Target

$31 -> $34

2025-09-08

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Rapport Therapeutics to $34 from $31 and keeps a Buy rating on the shares. The firm says RAP-219 surpassed its "most bullish expectations" with 71% reduction in long episodes and 78% reduction in clinical seizures. The data show "unimpeachable evidence" of the drug's effect and provide "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures, the analyst tells investors in a research note. H.C. Wainwright increased its probability of sucess for oral RAP-219 to 66% and peak revenue estimate to $766M from $613M.

Stifel

Buy

maintain

$35 -> $56

2025-09-08

Reason

Stifel

Price Target

$35 -> $56

2025-09-08

maintain

Buy

Reason

Stifel raised the firm's price target on Rapport Therapeutics to $56 from $35 and keeps a Buy rating on the shares after the company reported topline RAP-219 Phase 2a data in focal onset seizures that the firm says "clearly exceeded expectations." The effect-size is "so large that we are increasingly confident" in the probability-of-success for the Phase 3 trial, the analyst tells investors.

H.C. Wainwright

Buy

initiated

$31

2025-08-06

Reason

H.C. Wainwright

Price Target

$31

2025-08-06

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Rapport Therapeutics with a Buy rating and $31 price target. The firm believes RAP-219 could offer a \"unique\" clinical profile to address the unmet needs in epilepsy.

JMP Securities

Jason Butler

Buy

Initiates

$28

2025-04-08

Reason

JMP Securities

Jason Butler

Price Target

$28

2025-04-08

Initiates

Buy

Reason

Citizens JMP initiated coverage of Rapport Therapeutics with an Outperform rating and $28 price target. Rapport is developing novel precision therapeutics for central nervous system disorders leveraging receptor-associated proteins for targeted and selective function, the analyst tells investors in a research note. The firm believes this approach can produce clinical candidates differentiated from traditional treatments that target receptors distributed throughout the CNS by driving improved safety/tolerability profiles and broader therapeutic indexes.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Rapport Therapeutics Inc (RAPP.O) is -7.60, compared to its 5-year average forward P/E of -5.74. For a more detailed relative valuation and DCF analysis to assess Rapport Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.74

Current PE

-7.60

Overvalued PE

-3.44

Undervalued PE

-8.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.58

Undervalued EV/EBITDA

-5.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00